Zydus reveals positive data from Pegylated Interferon Alpha 2b trial
Category: #health  By Pankaj Singh  Date: 2021-04-05
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Zydus reveals positive data from Pegylated Interferon Alpha 2b trial

Zydus Cadila, an Indian pharmaceutical company, has reportedly revealed promising results from the Phase 3 Pegylated Interferon Alpha 2b, PegiHep™ clinical trials. As per the interim results, PegIFN can help in the rapid recovery of the COVID-19 patients following its early administration, thereby reducing the level of complications in its advanced stages.

The India-based firm has reportedly stated that the consumption of PegIFN by coronavirus-infected patients has various add-on advantages as compared to the anti-viral agents. As Pegylated Interferon Alpha 2b is a single-dose treatment regimen, it is also expected to be more affordable for these patients.

PegIFN, which comes in multiple doses, has been used to treat patients with chronic hepatitis B and C over the past years. During the recent Phase 3 clinical study, patients showed a low need for supplemental oxygen, indicating its ability to control respiratory failure and distress in treating the COVID-19 diseases.

Following the positive trial results of PegIFN, Zydus has applied for the approval of DCGI for an additional indication to treat COVID-19. The trials have demonstrated a two-point clinical improvement of the patients in the PegIFN arm as compared to the SOC (standard of care) arm on day 8. A higher patient proportion in the PegIFN arm was also found to be negative in the RT-PCR test by day 7, with the hours of supplemental oxygen needed were found to be significantly lesser in this arm. Moreover, the trial has shown a reduced time to resolution of the disease signs and symptoms.

According to Cadila Healthcare’s Dr. Sharvil Patel, MD, the company is encouraged by the positive results of the Phase 3 Pegylated Interferon alpha 2b trial, which can reduce the virus titres following early administration. This represents a milestone in the region, with Indian Innovation focusing on curbing the adverse impacts of the pandemic through the delivery of effective diagnostics, therapeutics, and vaccines.

Source credit:

https://www.expresspharma.in/covid19-updates/zydus-seeks-dcgi-nod-for-pegylated-interferon-alpha-2b-to-treat-covid-19/



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

MGMA partners with WhiteSpace Health to unveil MGMA DataDiscovery tool

By Pankaj Singh

Well-known medical practice management organization, Medical Group Management Association (MGMA) has reportedly joined forces with WhiteSpace Health to release a new medical group analytics tool, MGMA DataDiscovery. Th...

Santex acquires U.S. online retailer Parentgiving for market expansion

Santex acquires U.S. online retailer Parentgiving for market expansion

By Pankaj Singh

Italy-based personal care and incontinence product manufacturer Santex SPA has reportedly acquired Parentgiving Inc., America’s top-rated e-commerce retailer of geriatric care products.

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...